Cited by 2,770Cancer Cells and MetastasisDrug Transport and Resistance MechanismsCancer Genomics and Diagnostics

The DOI matches its Crossref record; 183 of the 188 references it cites were found in a registry or an index.

A view on drug resistance in cancer

Open access

Vasan, Neil, Baselga, José, Hyman, David M.·2019·Nature

DOI 10.1038/s41586-019-1730-1PMC PMC8008476

Open this paper in CoChat — free account Open PDF

Abstract

The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist approach to define and separate the key determinants of drug resistance, which include tumour burden and growth kinetics; tumour heterogeneity; physical barriers; the immune system and the microenvironment; undruggable cancer drivers; and the many consequences of applying therapeutic pressures. We propose four general solutions to drug resistance that are based on earlier detection of tumours permitting cancer interception; adaptive monitoring during therapy; the addition of novel drugs and improved pharmacological principles that result in deeper responses; and the identification of cancer cell dependencies by high-throughput synthetic lethality screens, integration of clinico-genomic data and computational modelling. These different approaches could eventually be synthesized for each tumour at any decision point and used to inform the choice of therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41586-019-1730-1

Cites

183 of 183 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
The Clonal Evolution of Tumor Cell Populations: Acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression.
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588

Show all 188 references

Research works printed but not linked: 1

Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727–1733 (1979).

Sorted by citations

Items 101–200 of 1,001

Potential of antibody–drug conjugates (ADCs) for cancer therapy
Marei, H. E. S., Cenciarelli, C., & Hasan, A. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02679-8 · Cited by 145
The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells
Kurimchak, A. M., Herrera-Montávez, C., Montserrat-Sangrà, S., Araiza-Olivera, D., Hu, J., Neumann-Domer, R., Kuruvilla, M., Bellacosa, A., Testa, J. R., Jin, J., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abn2707 · Cited by 136
Cell-penetrating peptides in protein mimicry and cancer therapeutics
Zorko, M., Jones, S., & Langel, Ü. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114044 · Cited by 136
Plant-Derived Nanovesicles: Further Exploration of Biomedical Function and Application Potential
Li, A., Li, D., Gu, Y., Liu, R., Tang, X., Zhao, Y., Qi, F., Wei, J., & Liu, J. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.022 · Cited by 137
The mini player with diverse functions: extracellular vesicles in cell biology, disease, and therapeutics
Thakur, A., Ke, X., Chen, Y., Motallebnejad, P., Zhang, K., Lian, Q., & Chen, H. J. (2021) · Protein & Cell · doi:10.1007/s13238-021-00863-6 · Cited by 138
Acquired resistance in cancer: towards targeted therapeutic strategies
Soragni, A., Knudsen, E. S., O’Connor, T. N., Tognon, C. E., Tyner, J. W., Gini, B., Kim, D., Bivona, T. G., Zang, X., Witkiewicz, A. K., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00824-9 · Cited by 151
Vessel co-option and resistance to anti-angiogenic therapy
Kuczynski, E. A., & Reynolds, A. R. (2019) · Angiogenesis · doi:10.1007/s10456-019-09698-6 · Cited by 138
Ferroptosis: An emerging approach for targeting cancer stem cells and drug resistance
Elgendy, S. M., Alyammahi, S. K., Alhamad, D. W., Abdin, S. M., & Omar, H. A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103095 · Cited by 134
Circular RNAs as biomarkers and therapeutic targets in cancer
Beilerli, A., Фанилевич, Г. И., Beylerli, O., Yang, G., Павлов, В. Н., Aliev, G., & Ahmad, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.026 · Cited by 133
Carboxylated chitosan-mediated improved efficacy of mesoporous silica nanoparticle-based targeted drug delivery system for breast cancer therapy
Lohiya, G., & Katti, D. S. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.118822 · Cited by 137
Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance
Song, J., Yang, P. X., Chen, C., Ding, W., Tillement, O., Bai, H., & Zhang, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02266-z · Cited by 159
Treatment resistance in diffuse large B-cell lymphoma
He, M. Y., & Kridel, R. (2021) · Leukemia · doi:10.1038/s41375-021-01285-3 · Cited by 134
Covalent organic framework nanomedicines: Biocompatibility for advanced nanocarriers and cancer theranostics applications
Singh, N., Kim, J., Kim, J., Lee, K., Zunbul, Z., Lee, I., Kim, E., Chi, S.-G., & Kim, J. S. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.08.016 · Cited by 133
New insights on sorafenib resistance in liver cancer with correlation of individualized therapy
Zhang, C., Wei-Qi, J., & Jin, D. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188382 · Cited by 131
A Systematic Strategy of Combinational Blow for Overcoming Cascade Drug Resistance via NIR‐Light‐Triggered Hyperthermia
Wang, L., Yu, Y., Wei, D., Zhang, L., Zhang, X., Zhang, G., Ding, D., Xiao, H., & Zhang, D. (2021) · Advanced Materials · doi:10.1002/adma.202100599 · Cited by 126
CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer
Vaghari‐Tabari, M., Hassanpour, P., Sadeghsoltani, F., Malakoti, F., Alemi, F., Qujeq, D., Asemi, Z., & Yousefi, B. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00348-2 · Cited by 137
Self-Assembled Organic Nanomaterials for Drug Delivery, Bioimaging, and Cancer Therapy
Zhang, Y., Fang, F., Li, L., & Zhang, J. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00883 · Cited by 129
Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes
Zhang, J., Cunningham, J. J., Brown, J. S., & Gatenby, R. A. (2022) · eLife · doi:10.7554/elife.76284 · Cited by 128
RETRACTED ARTICLE: Targeted activation of ferroptosis in colorectal cancer via LGR4 targeting overcomes acquired drug resistance
Zheng, H., Liu, J., Cheng, Q., Zhang, Q., Zhang, Y., Jiang, L., Huang, Y., Li, W., Zhao, Y., Chen, G., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00715-8 · Cited by 134
Retracted
Overcoming Cancer Drug Resistance Utilizing PROTAC Technology
Burke, M. R., Smith, A. R., & Zheng, G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.872729 · Cited by 129
Dysregulated Signalling Pathways Driving Anticancer Drug Resistance
Antoun, N. B., & Chioni, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512222 · Cited by 141
Glycogen Synthase Kinase 3β in Cancer Biology and Treatment
Domoto, T., Uehara, M., Bolidong, D., & Minamoto, T. (2020) · Cells · doi:10.3390/cells9061388 · Cited by 134
Targeting Src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models
Su, L., Chen, Y., Huang, C., Wu, S., Wang, X., Zhao, X., Xu, Q., Sun, R., Kong, X., Jiang, X., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abl7895 · Cited by 130
The Importance of Being PI3K in the RAS Signaling Network
Cuesta, C., Arévalo-Alameda, C., & Castellano, E. (2021) · Genes · doi:10.3390/genes12071094 · Cited by 125
LncRNA-encoded peptides in cancer
Zhang, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01591-0 · Cited by 131
CircRNAs in anticancer drug resistance: recent advances and future potential
Xu, T., Wang, M., Jiang, L., Ma, L., Wan, L., Chen, Q., Wei, C., & Wang, Z. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01240-3 · Cited by 125
Microfluidic Arrays of Breast Tumor Spheroids for Drug Screening and Personalized Cancer Therapies
Prince, E., Kheiri, S., Wang, Y., Xu, F., Cruickshank, J., Topolskaia, V., Tao, H., Young, E. W. K., McGuigan, A. P., Cescon, D. W., et al. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202101085 · Cited by 121
AXL in cancer: a modulator of drug resistance and therapeutic target
Tang, Y., Zang, H., Wen, Q., & Fan, S. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02726-w · Cited by 125
Breast cancer‐derived exosomes: Tumor progression and therapeutic agents
Jabbari, N., Akbariazar, E., Feqhhi, M., Rahbarghazi‬, R., & Rezaie, J. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29668 · Cited by 118
Activation of pyroptosis by specific organelle-targeting photodynamic therapy to amplify immunogenic cell death for anti-tumor immunotherapy
Zeng, S., Chen, C., Zhang, L., Liu, X., Qian, M., Cui, H., Wang, J., Chen, Q., & Peng, X. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.07.016 · Cited by 117
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies
Passaro, A., Janne, P. A., & Peters, S. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00013 · Cited by 126
Chemodynamic nanomaterials for cancer theranostics
Xin, J., Deng, C., Aras, Ö., Zhou, M., Wu, C., & An, F. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00936-y · Cited by 125
Insights Into Amentoflavone: A Natural Multifunctional Biflavonoid
Xiong, X., Tang, N., Lai, X., Zhang, J., Wen, W., Li, X., Li, A., Wu, Y., & Liu, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.768708 · Cited by 128
Co‐based Nanozymatic Profiling: Advances Spanning Chemistry, Biomedical, and Environmental Sciences
Li, J., Cai, X., Jiang, P., Wang, H., Zhang, S., Sun, T., Chen, C., & Fan, K. (2023) · Advanced Materials · doi:10.1002/adma.202307337 · Cited by 116
Role of Exosomal miRNAs and the Tumor Microenvironment in Drug Resistance
dos Santos, P. W. D. S., & Almeida, F. B. D. R. (2020) · Cells · doi:10.3390/cells9061450 · Cited by 114
Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy
Mantuano, N. R., Natoli, M., Zippelius, A., & Laubli, H. P. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001222 · Cited by 114
Antineoplastic Drug‐Free Anticancer Strategy Enabled by Host‐Defense‐Peptides‐Mimicking Synthetic Polypeptides
Shen, W. H., Zhang, Y., Wan, P., An, L., Zhang, P., Xiao, C., & Chen, X. (2020) · Advanced Materials · doi:10.1002/adma.202001108 · Cited by 112
Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity
Wright, S. C. E., Vasilevski, N., Serra, V., Rodon, J. A., & Eichhorn, P. J. A. (2021) · Cancers · doi:10.3390/cancers13071538 · Cited by 116
Drug resistance in cancer therapy: the Pandora's Box of cancer stem cells
Rezayatmand, H., Razmkhah, M., & Razeghian‐Jahromi, I. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02856-6 · Cited by 118
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer
Chiappa, M., Guffanti, F., Bertoni, F., Colombo, I., & Damia, G. L. M. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100744 · Cited by 113
The translational challenges of precision oncology
Pich, O., Bailey, C., Watkins, T. B. K., Zaccaria, S., Jamal‐Hanjani, M., & Swanton, C. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.002 · Cited by 116
In-situ TiO2-x decoration of titanium carbide MXene for photo/sono-responsive antitumor theranostics
Zhang, D., Liu, H., Younis, M. R., Lei, S., Chen, Y., Huang, P., & Lin, J. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01253-8 · Cited by 109
An overview of polymeric nanomicelles in clinical trials and on the market
Zheng, X., Xie, J., Zhang, X., Sun, W., Zhao, H., Li, Y., & Wang, C. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.11.029 · Cited by 112
Dissecting miRNA signature in colorectal cancer progression and metastasis
Huang, X., Zhu, X., Yu, Y., Zhu, W., Jin, L., Zhang, X., Li, S., Zou, P., Xie, C., & Cui, R. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.12.025 · Cited by 109
Kaempferol Can Reverse the 5-Fu Resistance of Colorectal Cancer Cells by Inhibiting PKM2-Mediated Glycolysis
Wu, H., Du, J., Li, C., Li, H., Guo, H., & Li, Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073544 · Cited by 110
Molecular mechanisms of ROS-modulated cancer chemoresistance and therapeutic strategies
Zhou, X., An, B., Lin, Y., Ni, Y., Zhao, X., & Liang, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115036 · Cited by 112
Prospects, advances and biological applications of MOF-based platform for the treatment of lung cancer
Deng, Y., Guo, M., Zhou, L., Huang, Y. S., Srivastava, S., Kumar, A., & Liu, J.-Q. (2024) · Biomaterials Science · doi:10.1039/d4bm00488d · Cited by 110
Crosstalk of pyroptosis and cytokine in the tumor microenvironment: from mechanisms to clinical implication
Wang, H., Wang, T., Yan, S., Tang, J., Zhang, Y., Wang, L., Xu, H., & Tu, C. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02183-9 · Cited by 122
Magnetic Measurement and Stimulation of Cellular and Intracellular Structures
Wang, X., Law, J., Luo, M., Gong, Z., Yu, J., Tang, W., Zhang, Z., Mei, X., Huang, Z., You, L., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c00959 · Cited by 110
Amino Acid Metabolism in Cancer Drug Resistance
Yoo, H.-C., & Han, J. M. (2022) · Cells · doi:10.3390/cells11010140 · Cited by 107
The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity
Salemme, V., Centonze, G., Avalle, L., Natalini, D., Piccolantonio, A., Arina, P., Morellato, A., Ala, U., Taverna, D., Turco, E., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1170264 · Cited by 106
Drug resistance in cancer: molecular mechanisms and emerging treatment strategies
Li, J., Hu, J., Yang, Y., Zhang, H., Liu, Y., Fang, Y., Qu, L., Lin, A., Luo, P., Jiang, A., et al. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00352-w · Cited by 120
Curcumin–cisplatin chemotherapy: A novel strategy in promoting chemotherapy efficacy and reducing side effects
Hussain, Y., Islam, L., Khan, H. Z., Filosa, R., Aschner, M., & Javed, S. (2021) · Phytotherapy Research · doi:10.1002/ptr.7225 · Cited by 100
Emerging Chemodynamic Nanotherapeutics for Cancer Treatment
Sun, D., Sun, X., Zhang, X., Wu, J., Shi, X., Sun, J., Luo, C., He, Z., & Zhang, S. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400809 · Cited by 102
RNA-based therapies: A cog in the wheel of lung cancer defense
Κhan, P., Siddiqui, J. A., Lakshmanan, I., Ganti, A. K., Salgia, R., Jain, M., Batra, S. K., & Nasser, M. W. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01338-2 · Cited by 104
All-in-One Molecular Aggregation-Induced Emission Theranostics: Fluorescence Image Guided and Mitochondria Targeted Chemo- and Photodynamic Cancer Cell Ablation
Guo, B., Wu, M., Shi, Q., Dai, T., Xu, S., Jiang, J., & Liu, B. (2020) · Chemistry of Materials · doi:10.1021/acs.chemmater.0c01187 · Cited by 98
Recent advances in phytochemical-based Nano-formulation for drug-resistant Cancer
More, M. P., Pardeshi, S. R., Pardeshi, C. V., Sonawane, G. A., Shinde, M. N., Deshmukh, P. K., Naik, J., & Kulkarni, A. D. (2021) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2021.100082 · Cited by 97
Clinical Applications and Anticancer Effects of Antimicrobial Peptides: From Bench to Bedside
Jafari, A., Babajani, A., Sarrami‐Forooshani, R., Yazdani, M., & Rezaei–Tavirani, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.819563 · Cited by 99
Targeting epigenetic regulatory machinery to overcome cancer therapy resistance
Guo, L., Lee, Y., Zhou, Y., & Huang, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.022 · Cited by 101
Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer
Gogleva, A. A., Polychronopoulos, D., Pfeifer, M., Poroshin, V., Ughetto, M., Martin, M. J., Thorpe, H., Bornot, A., Smith, P. D., Sidders, B. S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29292-7 · Cited by 95
Pluronic® triblock copolymer-based nanoformulations for cancer therapy: A 10-year overview
de Castro, K. C., Coco, J. C., dos Santos, É. M., Ataide, J. A., Martinez, R. M., Nascimento, M. H. M., Prata, J., Fonte, P., Severino, P. B., Mazzola, P. G., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.017 · Cited by 96
Organoid engineering with microfluidics and biomaterials for liver, lung disease, and cancer modeling
Kim, S. K., Kim, Y. H., Park, S., & Cho, S. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.03.002 · Cited by 96
Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches
Ghosh, S., Javia, A., Shetty, S. R., Bardoliwala, D., Maiti, K., Banerjee, S., Khopade, A. J., Misra, A. R., Sawant, K. K., & Bhowmick, S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.07.014 · Cited by 95
Targeting Lysosomes in Cancer as Promising Strategy to Overcome Chemoresistance—A Mini Review
Geisslinger, F., Müller, M. J., Vollmar, A. M., & Bartel, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01156 · Cited by 98
Clinical translation of patient-derived tumour organoids- bottlenecks and strategies
Foo, M. A., You, M., Chan, S. L., Sethi, G., Bonney, G. K., Yong, W. P., Chow, E. K., Fong, E. L. S., Wang, L., & Goh, B.-C. (2022) · Biomarker Research · doi:10.1186/s40364-022-00356-6 · Cited by 100
Recent advances in augmenting Fenton chemistry of nanoplatforms for enhanced chemodynamic therapy
Li, S., Chu, X., Dong, H., Hou, H., & Liu, Y. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.215004 · Cited by 95
Polymeric photothermal agents for cancer therapy: recent progress and clinical potential
Du, C., Wu, X., He, M., Zhang, Y., Zhang, R., & Dong, C. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb02659j · Cited by 93
Stimuli‐Responsive PROTACs for Controlled Protein Degradation
An, K., Deng, X., Chi, H., Zhang, Y., Li, Y., Cheng, M., Ni, Z., Yang, Z., Wang, C., Chen, J., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202306824 · Cited by 95
SGK1 in Human Cancer: Emerging Roles and Mechanisms
Sang, Y., Kong, P., Zhang, S., Zhang, L., Cao, Y., Duan, X., Sun, T., Tao, Z., & Liu, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.608722 · Cited by 96
Inhibition of the PLK1‐Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer
Yu, Z., Deng, P., Chen, Y., Liu, S., Chen, J., Yang, Z., Chen, J., Fan, X., Wang, P., Cai, Z., et al. (2021) · Advanced Science · doi:10.1002/advs.202100759 · Cited by 91
Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden
Zhu, G., Guo, Y. A., Ho, D., Poon, P. S. Y., Poh, Z. W., Wong, P., Gan, A., Chang, M. M., Kleftogiannis, D., Lau, Y. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22463-y · Cited by 90
Experimental Evidence for Therapeutic Potentials of Propolis
Bhargava, P., Mahanta, D., Kaul, A., Ishida, Y., Terao, K., Wadhwa, R., & Kaul, S. C. (2021) · Nutrients · doi:10.3390/nu13082528 · Cited by 100
Helicobacter pylori–induced RASAL2 Through Activation of Nuclear Factor-κB Promotes Gastric Tumorigenesis via β-catenin Signaling Axis
Cao, L., Zhu, S., Lu, H., Soutto, M., Bhat, N. S., Chen, Z., Peng, D., Lin, J., Lu, J. K., Li, P., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.01.046 · Cited by 92
Mesenchymal stem cells: A living carrier for active tumor-targeted delivery
Zhang, T., Lin, R., Wu, H., Jiang, X., & Gao, J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114300 · Cited by 90
Single duplex DNA sequencing with CODEC detects mutations with high sensitivity
Bae, J. H., Liu, R., Roberts, E., Nguyen, E., Tabrizi, S., Rhoades, J., Blewett, T., Xiong, K., Gydush, G., Shea, D., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01376-0 · Cited by 94
Emerging artificial intelligence-driven precision therapies in tumor drug resistance: recent advances, opportunities, and challenges
Mao, Y., Shangguan, D., Huang, Q., Xiao, L., Cao, D., Zhou, H., & Wang, Y. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02321-x · Cited by 90
The Hippo Signaling Pathway in Drug Resistance in Cancer
Zeng, R., & Dong, J. (2021) · Cancers · doi:10.3390/cancers13020318 · Cited by 89
Neisseria meningitidis Opca Protein/MnO2 Hybrid Nanoparticles for Overcoming the Blood–Brain Barrier to Treat Glioblastoma
Dong, C., Huang, Q., Cheng, H. L., Zheng, D., Hong, S., Yan, Y. Q., Niu, M., Xu, J., & Zhang, X. (2022) · Advanced Materials · doi:10.1002/adma.202109213 · Cited by 90
Dynamic regulation of RAS and RAS signaling
Kölch, W., Berta, D., & Rosta, E. (2023) · Biochemical Journal · doi:10.1042/bcj20220234 · Cited by 92
MnO 2 -Based nanosystems for cancer therapy
Wen, J., Yang, K., & Sun, S. (2020) · Chemical Communications · doi:10.1039/d0cc02782k · Cited by 89
Ultrasound‐Augmented Nanocatalytic Ferroptosis Reverses Chemotherapeutic Resistance and Induces Synergistic Tumor Nanotherapy
Zheng, Y., Li, X., Dong, C., Ding, L., Huang, H., Zhang, T., Chen, Y., & WU, R. T. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202107529 · Cited by 88
Nanomedicine Combats Drug Resistance in Lung Cancer
Zheng, X., Song, X.-H., Zhu, G., Pan, D., Li, H., Hu, J., Xiao, K., Gong, Q., Gu, Z., Luo, K., et al. (2023) · Advanced Materials · doi:10.1002/adma.202308977 · Cited by 94
A patient-specific lung cancer assembloid model with heterogeneous tumor microenvironments
Zhang, Y., Hu, Q., Pei, Y., Luo, H., Wang, Z., Xu, X., Zhang, Q. H., Dai, J., Wang, Q., Fan, Z., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47737-z · Cited by 92
Nanomaterial-based regulation of redox metabolism for enhancing cancer therapy
Jia, X., Wang, Y., Qiao, Y., Jiang, X., & Li, J. (2024) · Chemical Society Reviews · doi:10.1039/d4cs00404c · Cited by 87
Exploiting the acquired vulnerability of cisplatin-resistant tumors with a hypoxia-amplifying DNA repair–inhibiting (HYDRI) nanomedicine
Chen, J., Wang, X., Yuan, Y., Chen, H., Zhang, L., Xiao, H., Chen, J., Zhao, Y., Chang, J. K., Guo, W., et al. (2021) · Science Advances · doi:10.1126/sciadv.abc5267 · Cited by 86
Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer
Sharma, M., Bakshi, A. K., Mittapelly, N., Gautam, S., Marwaha, D., Rai, N., Singh, N., Tiwari, P., Agarwal, N., Kumar, A., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.007 · Cited by 84
Therapeutic Potential of Natural Products in Treatment of Cervical Cancer: A Review
Park, S., Kim, M., Lee, S., Jung, W., & Kim, B. (2021) · Nutrients · doi:10.3390/nu13010154 · Cited by 85
A Review of ULK1-Mediated Autophagy in Drug Resistance of Cancer
Liu, L., Yan, L., Liao, N., Wu, W.-Q., & Shi, J. (2020) · Cancers · doi:10.3390/cancers12020352 · Cited by 86
Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance
Li, G., Qu, Q., Qi, T.-T., Teng, X.-Q., Zhu, H., Wang, J., Lu, Q., & Qu, J. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01974-y · Cited by 89
A Nanoarchitectonic Approach Enables Triple Modal Synergistic Therapies To Enhance Antitumor Effects
Mo, Z., Li, Q., Zhao, K., Xu, Q., Hu, H., Xu, C., Luo, Y., Chi, B., Liu, L., Fang, X., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c20416 · Cited by 84
Interactions between Dietary Antioxidants, Dietary Fiber and the Gut Microbiome: Their Putative Role in Inflammation and Cancer
Munteanu, C., & Schwartz, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158250 · Cited by 93
CircPIAS1 promotes hepatocellular carcinoma progression by inhibiting ferroptosis via the miR-455-3p/NUPR1/FTH1 axis
Zhang, X.-Y., Li, S.-S., Gu, Y.-R., Xiao, L.-X., Ma, X.-Y., Chen, X.-R., Wang, J.-L., Liao, C.-H., Lin, B.-L., Huang, Y.-H., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02030-x · Cited by 80
KRAS G12C Mutations in NSCLC: From Target to Resistance
Addeo, A., Banna, G. L., & Friedlaender, A. (2021) · Cancers · doi:10.3390/cancers13112541 · Cited by 85
Metal organic framework-coated gold nanorod as an on-demand drug delivery platform for chemo-photothermal cancer therapy
Huang, J., Xu, Z., Jiang, Y., Law, W., Dong, B., Zeng, X., Ma, M., Xu, G., Zou, J., & Yang, C. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00961-x · Cited by 88
Anti-Cancer Activity of Sustained Release Capsaicin Formulations
Merritt, J. C., Richbart, S. D., Moles, E. G., Cox, A. J., Brown, K. C., Miles, S. L., Finch, P. T., Hess, J. A., Tirona, M. T., Valentovic, M. A., et al. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108177 · Cited by 90
Chromosomal instability and aneuploidy as causes of cancer drug resistance
Lukow, D. A., & Sheltzer, J. M. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.09.002 · Cited by 83
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors
Cocco, E., Lee, J. E., Kannan, S., Schram, A. M., Won, H. H., Shifman, S. G., Kulick, A. R., Baldino, L., Toska, E., Arruabarrena-Aristorena, A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0571 · Cited by 83
Self-citation
Necroptosis Induced by Ruthenium(II) Complexes as Dual Catalytic Inhibitors of Topoisomerase I/II
Xiong, K., Qian, C., Yuan, Y., Wei, L., Liao, X., He, L., Rees, T. W., Chen, Y., Wan, J., Ji, L., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202006089 · Cited by 80
Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors
Agnello, L., Tortorella, S., d’Argenio, A., Carbone, C., Camorani, S., Locatelli, E., Auletta, L., Sorrentino, D., Fedele, M., Zannetti, A., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02039-w · Cited by 80
RNA-binding protein ZCCHC4 promotes human cancer chemoresistance by disrupting DNA-damage-induced apoptosis
Zhu, H., Chen, K., Chen, Y., Liu, J., Zhang, X., Zhou, Y., Liu, Q., Wang, B., Chen, T., & Cao, X. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01033-8 · Cited by 80

Authors: Vasan, N., Baselga, J., & Hyman, D. M.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Hyman, David M.
ORCID: Vasan, Neil
Hyman, David M.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2019-11-13
Volume: 575
Issue: 7782
Pages: 299-309
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-019-1730-1
PMC: PMC8008476
OpenAlex: W2988773550
Cited by: 2,770
References: 188
Citations by year: 2026: 344 · 2025: 533 · 2024: 524 · 2023: 467 · 2022: 397 · 2021: 346 · 2020: 150 · 2019: 4
FWCI: 21.44
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Eli Lilly and Company
National Cancer Institute (R01CA207244, R01CA190642, P30CA008748, T32CA009207)
Topics: Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: chemoresistance, tumor heterogeneity, tumor microenvironment, tumor immune evasion, tumor growth kinetics, tumor burden, early cancer detection, adaptive monitoring, synthetic lethality screen, precision oncology
MeSH terms: Antineoplastic Agents, Humans, Models, Biological, Neoplasms, Drug Resistance, Neoplasm, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A view on drug resistance in cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks